Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for immune-mediated diseases. Its lead asset, envudeucitinib (envu), is an allosteric TYK2 inhibitor in Phase 3 trials for plaque psoriasis and Phase 2 for SLE, with NDA submission planned for 2026. Its pipeline also includes A-005, a CNS-penetrant TYK2 inhibitor, and lonigutamab, a monoclonal antibody targeting IGF-1R for Thyroid Eye Disease, acquired via the ACELYRIN merger.
Q2 FY2026 — expected 2026-09-06
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-19 | 2025-12-31 | 0001847367-26-000006 | EDGAR | 130K words |
| 2025-03-19 | 2024-12-31 | 0001847367-25-000012 | EDGAR | 108K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-13 | 2026-06-30 | 0001847367-26-000018 | EDGAR | 85K words |
| 2025-11-13 | 2025-09-30 | 0001847367-25-000050 | EDGAR | 88K words |
| 2025-08-13 | 2025-06-30 | 0001847367-25-000041 | EDGAR | 88K words |
| 2025-05-14 | 2025-03-31 | 0001847367-25-000028 | EDGAR | 81K words |
| 2024-11-13 | 2024-09-30 | 0001847367-24-000005 | EDGAR | 75K words |
| 2024-08-13 | 2024-06-30 | 0001558370-24-012081 | EDGAR | 77K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-01 | 0001104659-26-104145 | EDGAR | 4K words |
| 2026-08-13 | 0001847367-26-000016 | EDGAR | 3K words |
| 2026-08-10 | 0001104659-26-093353 | EDGAR | 2K words |
| 2026-03-30 | 0001104659-26-036386 | EDGAR | 4K words |
| 2026-03-19 | 0001847367-26-000004 | EDGAR | 3K words |
| 2026-01-09 | 0001104659-26-002265 | EDGAR | 19K words |
| 2026-01-06 | 0001104659-26-001073 | EDGAR | 4K words |
| 2026-01-02 | 0001104659-26-000197 | EDGAR | 1K words |
| 2025-11-13 | 0001847367-25-000048 | EDGAR | 3K words |
| 2025-09-03 | 0001104659-25-086612 | EDGAR | 6K words |
46 total filings indexed. 28 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001847367 |
| Ticker | ALMS |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.alumis.com |
| Listed | 2024-06-28 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ALMS (~200 tokens, structured JSON with cryptographic provenance)